1
|
Braga A, Izolan JS, Costa TCD, Araújo BVD. Free interstitial levels of metformin in the liver of healthy and diabetic Wistar rats. BRAZ J PHARM SCI 2022. [DOI: 10.1590/s2175-97902022e19674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
2
|
Carreño F, Helfer VE, Staudt KJ, Olivo LB, Paese K, Meyer FS, Herrmann AP, Guterres SS, Kuze Rates SM, Trocóniz I, Dalla Costa T. Semi-Mechanistic Pharmacokinetic Modeling of Lipid Core Nanocapsules: Understanding Quetiapine Plasma and Brain Disposition in a Neurodevelopmental Animal Model of Schizophrenia. J Pharmacol Exp Ther 2020; 375:49-58. [PMID: 32719070 DOI: 10.1124/jpet.120.000109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/14/2020] [Indexed: 11/22/2022] Open
Abstract
This study investigated plasma and brain disposition of quetiapine lipid core nanocapsules (QLNC) in naive and schizophrenic (SCZ-like) rats and developed a semimechanistic model to describe changes in both compartments following administration of the drug in solution (FQ) or nanoencapsulated. QLNC (1 mg/ml) presented 166 ± 39 nm, low polydispersity, and high encapsulation (93.0% ± 1.4%). A model was built using experimental data from total and unbound plasma and unbound brain concentrations obtained by microdialysis after administration of single intravenous bolus dose of FQ or QLNC to naive and SCZ-like rats. A two-compartment model was identifiable both in blood and in brain with a bidirectional drug transport across the blood-brain barrier (CLin and CLout). SCZ-like rats' significant decrease in brain exposure with FQ (decrease in CLin) was reverted by QLNC, showing that nanocarriers govern quetiapine tissue distribution. Model simulations allowed exploring the potential of LNC for brain delivery. SIGNIFICANCE STATEMENT: A population approach was used to simultaneously model total and unbound plasma and unbound brain quetiapine concentrations allowing for quantification of the rate and extent of the drug's brain distribution following administration of both free drug in solution or as nanoformulation to naive and SCZ-like rats. The model-based approach is useful to better understand the possibilities and limitations of this nanoformulation for drug delivering to the brain, opening the opportunity to use this approach to improve SCZ-treatment-limited response rates.
Collapse
Affiliation(s)
- Fernando Carreño
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Victória Eteges Helfer
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Keli Jaqueline Staudt
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Laura Bem Olivo
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Karina Paese
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Fabíola Schons Meyer
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Ana Paula Herrmann
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Sílvia Stanisçuaski Guterres
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Stela Mari Kuze Rates
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Iñaki Trocóniz
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| | - Teresa Dalla Costa
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia (F.C., V.E.H., K.J.S., L.B.O., K.P., S.S.G., S.M.K.R., T.D.C.), Centro de Reprodução e Experimentação de Animais de Laboratório, Instituto de Ciências Básicas da Saúde (F.S.M.), and Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde (A.P.H.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (I.T.); and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain (I.T.)
| |
Collapse
|
3
|
Lorenzoni R, Barreto F, Contri RV, de Araújo BV, Pohlman AR, Costa TD, Guterres SS. Rapid and sensitive LC-MS/MS method for simultaneous quantification of capsaicin and dihydrocapsaicin in microdialysis samples following dermal application. J Pharm Biomed Anal 2019; 173:126-133. [DOI: 10.1016/j.jpba.2019.05.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Revised: 05/13/2019] [Accepted: 05/14/2019] [Indexed: 11/16/2022]
|
4
|
Zhang L, Yao L, Kang Z, Huang Z, Gu X, Shen X, Ding H. Microdialysis Determination of Cefquinome Pharmacokinetics in Murine Thigh From Healthy, Neutropenic, and Actinobacillus pleuropneumoniae-Infected Mice. Front Pharmacol 2019; 10:249. [PMID: 30914957 PMCID: PMC6422941 DOI: 10.3389/fphar.2019.00249] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Accepted: 02/26/2019] [Indexed: 11/19/2022] Open
Abstract
This study was aimed at applying microdialysis to explore cefquinome pharmacokinetics in thigh and plasma of healthy, neutropenic, and Actinobacillus pleuropneumoniae-infected mice. The relative recoveries (RRs) were tested in vitro by dialysis and retrodialysis and in vivo by retrodialysis. ICR mice were randomly divided into four groups: H-40 (healthy mice receiving cefquinome at 40 mg/kg), H-160, N-40 (neutropenic mice), and I-40 mg/kg (thigh infected-mice with A. pleuropneumoniae). After cefquinome administration, plasma was collected by retro-orbital puncture and thigh dialysate was collected by using a microdialysis probe with Ringer’s solution at a perfusion rate of 1.5 μL/min. Plasma and thigh dialysate samples were assessed by HPLC–MS/MS and analyzed by a non-compartment model. The mean in vivo recoveries in the thigh were 39.35, 38.59, and 37.29% for healthy, neutropenic, and infected mice, respectively. The mean plasma protein-binding level was 16.40% and was independent of drug concentrations. For all groups, the mean values of the free AUCinf in plasma were higher than those in murine thigh, while the elimination T1/2β for plasma were lower than those for murine thigh. Cefquinome penetration (AUCthigh/AUCplasma) from the plasma to thigh was 0.76, 0.88, 0.47, and 0.98 for H-40, N-40, I-40, and H-160 mg/kg, respectively. These results indicated that infection significantly affected cefquinome pharmacokinetics in murine thigh. In conclusion, we successfully applied a microdialysis method to evaluate the pharmacokinetics of cefquinome in murine thigh of healthy, neutropenic, and A. pleuropneumonia-infected mice and the pharmacokinetics of cefquinome was obviously affected by infection in thigh.
Collapse
Affiliation(s)
- Longfei Zhang
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Lihua Yao
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Zheng Kang
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Zilong Huang
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Xiaoyan Gu
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Xiangguang Shen
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| | - Huanzhong Ding
- Guangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
| |
Collapse
|
5
|
Kirbs C, Kluwe F, Drescher F, Lackner E, Matzneller P, Weiss J, Zeitlinger M, Kloft C. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Eur J Pharm Sci 2019; 131:218-229. [PMID: 30731238 DOI: 10.1016/j.ejps.2019.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 12/20/2018] [Accepted: 02/03/2019] [Indexed: 01/18/2023]
Abstract
Voriconazole, a broad-spectrum antifungal drug used to prevent and treat invasive fungal infections, shows complex pharmacokinetics and is primarily metabolised by various CYP enzymes. An adequate unbound antibiotic concentration-time profile at the target-site of an infection is crucial for effective prophylaxis or therapy success. Therefore, the aim was to evaluate the pharmacokinetics of voriconazole after the approved sequence dosing in healthy volunteers in interstitial space fluid, assessed by microdialysis, and in plasma. Moreover, potential pharmacogenetic influences of CYP2C19 polymorphisms on pharmacokinetics were investigated. The prospective, open-labelled, uncontrolled long-term microdialysis study included 9 healthy male individuals receiving the approved sequence dosing regimen for voriconazole. Unbound voriconazole concentrations were sampled over 84 h in interstitial space fluid of subcutaneous adipose tissue and in plasma and subsequently quantified via high-performance liquid chromatography. For pharmacokinetic data analysis, non-compartmental analysis was used. High interindividual variability in voriconazole concentration-time profiles was detected although dosing was adapted to body weight for the first intravenous administrations. Due to nonlinear pharmacokinetics, target-site exposure of voriconazole in healthy volunteers was found to be highly comparable to plasma exposure, particularly after multiple dosing. Regarding the CYP2C19 genotype-predicted phenotype, the individuals revealed a broad spectrum, ranging from poor to rapid metaboliser status. A strong relation between CYP2C19 genotype-predicted phenotype and voriconazole clearance was identified.
Collapse
Affiliation(s)
- Claudia Kirbs
- Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstraße 31, 12169 Berlin, Germany; Department of Clinical Pharmacy, Institute of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany.
| | - Franziska Kluwe
- Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstraße 31, 12169 Berlin, Germany; Graduate Research Training Program PharMetrX, Germany.
| | - Franziska Drescher
- Department of Clinical Pharmacy, Institute of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany
| | - Edith Lackner
- Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | - Peter Matzneller
- Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | - Johanna Weiss
- Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
| | - Markus Zeitlinger
- Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | - Charlotte Kloft
- Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstraße 31, 12169 Berlin, Germany; Department of Clinical Pharmacy, Institute of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany.
| |
Collapse
|
6
|
Wei Y, Luo X, Guan J, Ma J, Zhong Y, Luo J, Li F. Biodegradable nanoparticles for improved kidney bioavailability of rhein: preparation, characterization, plasma, and kidney pharmacokinetics. Drug Dev Ind Pharm 2017; 43:1885-1891. [DOI: 10.1080/03639045.2017.1353519] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Yinghui Wei
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Xiaoting Luo
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Jiani Guan
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Jianping Ma
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Yicong Zhong
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Jingwen Luo
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| | - Fanzhu Li
- College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
| |
Collapse
|
7
|
Application of a LC-MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis. J Pharm Biomed Anal 2016; 134:340-345. [PMID: 27823925 DOI: 10.1016/j.jpba.2016.10.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 10/19/2016] [Accepted: 10/26/2016] [Indexed: 11/22/2022]
Abstract
A bioanalytical LC-MS/MS method was developed and validated to determine tobramycin in plasma and lung microdialysate samples. Tobramycin was separated using a C18 column and a mobile phase consisting of water and acetonitrile, both with 10mM of heptafluorobutyric acid, eluted as gradient. Apramycin was used as internal standard (IS) for plasma samples. Drugs were monitored using electrospray ionization operating on positive mode (ESI+) monitoring the transitions 468.2>163.3 m/z for tobramycin and 540.3>217.2 m/z for IS. The method showed linearity in the concentration range of 0.1-50μgmL-1 for microdialysate and 0.5-100μgmL-1 for plasma with coefficients of determination ≥0.991. The inter- and intra-day precision, the accuracy and the stability of the drug in different conditions were in accordance with the limits established by US Food and Drug Administration guideline. The concentrations of tobramycin in plasma and lung microdialysate, determined using CMA/20 probes and a Ringer solution at a flow rate of 1μLmin-1, were evaluated in healthy Wistar rats after a 10mgkg-1 i.v. bolus dose. Samples were harvested up to 12h post-dose. Before animal's experiments, probe recovery was determined by dialysis and retrodialysis in vitro and by retrodialysis in vivo. Probes recovery was independent of drug concentration and method of determination. In vivo recovery was 27.74±7.70%. Pharmacokinetic parameters were estimated by non-compartmental analysis using the software Phoenix®. The estimated area under the curve (AUC0-∞) was 128±19μghmL-1 and 105±12μghmL-1 for plasma and lung, respectively. Tobramycin plasma clearance was 0.07±0.01L/h/kg and the volume of distribution was 0.49±0.09L/kg. Elimination half-life in plasma was 4.4±0.7h and in lung, 4.2±0.56h. The free tissue/free plasma AUC0-∞ ratio was 0.94. This is the first study showing a validated method to quantify tobramycin in microdialysate samples and to evaluate the lung interstitial concentration of the drug.
Collapse
|
8
|
Carreño F, Paese K, Silva CM, Guterres SS, Dalla Costa T. Pharmacokinetic Investigation of Quetiapine Transport across Blood-Brain Barrier Mediated by Lipid Core Nanocapsules Using Brain Microdialysis in Rats. Mol Pharm 2016; 13:1289-97. [PMID: 26905300 DOI: 10.1021/acs.molpharmaceut.5b00875] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Lipid-core nanocapsules (LCNs) have been proposed as drug carriers to improve brain delivery by modulating drug pharmacokinetics (PK). However, it is not clear whether the LCNs carry the drug through the blood-brain barrier or increase free drug penetration due to changes in the barrier permeability. Quetiapine (QTP) penetration to the brain is mediated by influx transporters and therefore might be reduced by drug transporters inhibitiors as probenecid. The goal of this work was to investigate the role of type-III LCNs on brain penetration of QTP using microdialysis in the presence probenecid. QTP-loaded LCN (QLNC) was successfully obtained with a small particle size (143 ± 6 nm), low polydispersity index (PI < 0.1), and high encapsulation efficiency (95.4 ± 1.82%.). Total and free drug concentration in plasma and free drug concentration in brain were analyzed following i.v. bolus dosing of nonencapsulated drug (FQ) and QLNC formulations alone and in association with probenecid to male Wistar rats. QTP free plasma fraction right after administration of QLNC was smaller than the fraction observed after FQ dosing; however, it increased over time until similar free drug levels were attained, suggesting that type-III LNCs produce a short in vivo sustained release of the drug. The inhibition of influx transporters by PB led to a reduction of free QTP brain penetration, as observed by the reduction of penetration factor from 1.55 ± 0.17 to a value closer to unit (0.94 ± 0.15). However, when the drug was nanoencapsulated, the inhibition of influx transporters had no effect on the brain penetration factor (0.88 ± 0.21 to 0.92 ± 0.13) probably because QTP is loaded into LNC and not available to interact with transporters. Taken together, these results suggest that LNC type-III carried QTP in the bloodstream and delivered the drug to the brain.
Collapse
Affiliation(s)
- Fernando Carreño
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul , Av. Ipiranga, 2759, 90610-000 Porto Alegre, Rio Grande do Sul, RS, Brazil
| | - Karina Paese
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul , Av. Ipiranga, 2759, 90610-000 Porto Alegre, Rio Grande do Sul, RS, Brazil
| | - Carolina Miranda Silva
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul , Av. Ipiranga, 2759, 90610-000 Porto Alegre, Rio Grande do Sul, RS, Brazil
| | - Silvia S Guterres
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul , Av. Ipiranga, 2759, 90610-000 Porto Alegre, Rio Grande do Sul, RS, Brazil
| | - Teresa Dalla Costa
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul , Av. Ipiranga, 2759, 90610-000 Porto Alegre, Rio Grande do Sul, RS, Brazil
| |
Collapse
|
9
|
Azeredo FJ, Hass SE, Sansone P, Derendorf H, Costa TD, De Araujo BV. Does the Anesthetic Urethane Influence the Pharmacokinetics of Antifungal Drugs? A Population Pharmacokinetic Investigation in Rats. J Pharm Sci 2015; 104:3314-8. [DOI: 10.1002/jps.24552] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 05/20/2015] [Accepted: 05/21/2015] [Indexed: 11/07/2022]
|
10
|
Wei Y, Guan J, Ma X, Zhong Y, Ma J, Li F. Effect of glycyrrhizic acid on rhein renal penetration: a microdialysis study in rats. Xenobiotica 2015; 45:1116-21. [DOI: 10.3109/00498254.2015.1043660] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
11
|
Monterrubio C, Paco S, Vila-Ubach M, Rodríguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J, Carcaboso AM. Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. Pharm Res 2015; 32:2889-900. [PMID: 25773723 DOI: 10.1007/s11095-015-1671-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 03/06/2015] [Indexed: 12/12/2022]
Abstract
PURPOSE To develop a reproducible microdialysis-tumor homogenate method for the study of the intratumor distribution of a highly hydrophobic anticancer drug (SN-38; 7-ethyl-10-hydroxycamptothecin) in neuroblastoma patient-derived xenografts. METHODS We studied the nonspecific binding of SN-38 to the microdialysis tubing in the presence of 2-hydroxypropyl-beta-cyclodextrin (HPBCD) in the perfusate. We calibrated the microdialysis probes by the zero flow rate (ZFR) method and calculated the enhancement factor (f = extrapolated SN-38 concentration at the ZFR / SN-38 concentration in the dialysed solution) of HPBCD. We characterized the extravasation of HPBCD to tumors engrafted in mice. In vivo microdialysis and terminal homogenate data at the steady state (subcutaneous pump infusions) were used to calculate the volume of distribution of unbound SN-38 (Vu,tumor) in neuroblastoma. RESULTS HPBCD (10% w/v) in the perfusate prevented the nonspecific binding of SN-38 to the microdialysis probe and enhanced SN-38 recovery (f = 1.86). The extravasation of HPBCD in the tumor during microdialysis was lower than 1%. Vu,tumor values were above 3 mL/g tumor for both neuroblastoma models and suggested efficient cellular penetration of SN-38. CONCLUSIONS The method contributes to overcome the limitations of the microdialysis technique in hydrophobic drugs and provides a powerful tool to characterize compartmental anticancer drug distribution in xenografts.
Collapse
Affiliation(s)
- Carles Monterrubio
- Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pigatto MC, Mossmann DL, Dalla Costa T. HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. Biomed Chromatogr 2014; 29:529-36. [DOI: 10.1002/bmc.3308] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 06/18/2014] [Accepted: 07/17/2014] [Indexed: 11/11/2022]
Affiliation(s)
- Maiara Cássia Pigatto
- Pharmaceutical Sciences Graduate Program; College of Pharmacy, Federal University of Rio Grande do Sul; Porto Alegre Brazil
- Centro Bioanalítico de Medicamentos; College of Pharmacy, Federal University of Rio Grande do Sul; Porto Alegre Brazil
| | - Daniele Lenz Mossmann
- Centro Bioanalítico de Medicamentos; College of Pharmacy, Federal University of Rio Grande do Sul; Porto Alegre Brazil
| | - Teresa Dalla Costa
- Pharmaceutical Sciences Graduate Program; College of Pharmacy, Federal University of Rio Grande do Sul; Porto Alegre Brazil
- Centro Bioanalítico de Medicamentos; College of Pharmacy, Federal University of Rio Grande do Sul; Porto Alegre Brazil
| |
Collapse
|
13
|
de Andrade C, de Araújo Lock G, Pigatto MC, Haas SE, Costa TD, de Araújo BV. Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis. Biomed Chromatogr 2014; 28:1722-7. [PMID: 24771661 DOI: 10.1002/bmc.3212] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Revised: 02/26/2014] [Accepted: 03/15/2014] [Indexed: 01/02/2023]
Abstract
A novel LC-MS/MS method was developed for the quantification of vildagliptin in an aqueous matrix. The method was successfully validated, meeting all the requisites of US Food and Drug Administration guide for a bioanalytical method. The developed method presented a limit of quantification of 10 ng/mL and the range of concentration achieved was 10-1875 ng/mL. The injection volume necessary was only 10 μL, and retention time was 4.60 min. The mobile phase employed was methanol-ammonium acetate 5 mm (95:5). The stability of the drug was evaluated in the different conditions through which the samples passed. A pharmacokinetic experiment was conducted with diabetic male Wistar rats, and the concentration of drug in liver was evaluated through a microdialysis technique. The perfusion fluid employed was ultrapure water. The dose administrated was 50 mg/kg and the method allowed the quantification of vildagliptin for more than three half lives, successfully characterizing the pharmacokinetic profile when the developed method was applied. This is the first report on the tissue pharmacokinetics of a DPP-4 inhibitor and could contribute to drug dosage optimization in the future.
Collapse
Affiliation(s)
- Cristiane de Andrade
- Programa de Pós-Graduacão em Ciências Farmacêuticas, UniversidadeFederal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre CEP, 90610-000, RS, Brazil
| | | | | | | | | | | |
Collapse
|
14
|
Smith KM, Maxwell L, Gull T, Payton ME, Gilmour MA. Stability of 1% voriconazole solution in a constant-rate infusion pump for topical ocular delivery to horses. Vet Ophthalmol 2014; 17 Suppl 1:82-9. [PMID: 24602272 DOI: 10.1111/vop.12155] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To establish the effect of storage in a constant-rate infusion (CRI) pump on the sterility and stability of voriconazole 1% solution. PROCEDURE Nine vials of voriconazole (Vfend(®) I.V.) 1% solution were prepared. Approximately half of each solution was used to prime a commercially available CRI pump with attached subpalpebral lavage system (CRI/SPL unit) with the remaining solution stored in the commercial glass vial. Three CRI/SPL units and their three corresponding vials were stored at one of three temperatures: 23 °C, 33 °C, and 40 °C. The CRI pumps ran for 7 days, and the vials were stored for 30 days. Fungal and aerobic bacterial cultures were performed on the first and last day of the storage period for each vessel. Samples were obtained at regular intervals for determination of voriconazole concentration using high-performance liquid chromatography. RESULTS No bacterial or fungal contamination was identified in any solution at any time point. All solutions stored in the commercial glass vial remained stable throughout the study period. Multiple CRI/SPL units became blocked with crystallized voriconazole. There was a significant increase in voriconazole concentration after passage through the CRI/SPL units. CONCLUSIONS Voriconazole 1% solution is not compatible for use in a CRI/SPL unit at temperatures between 23 and 40 °C. Voriconazole 1% solution is stable in the commercial glass vial when stored at controlled temperatures as high as 40 °C for up to 30 days.
Collapse
Affiliation(s)
- Kathryn M Smith
- Department of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, 74078, USA
| | | | | | | | | |
Collapse
|
15
|
Simmel F, Kirbs C, Erdogan Z, Lackner E, Zeitlinger M, Kloft C. Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans. AAPS JOURNAL 2012; 15:95-103. [PMID: 23065438 DOI: 10.1208/s12248-012-9412-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 09/11/2012] [Indexed: 11/30/2022]
Abstract
Reliable drug concentration measurements at the target site are increasingly demanded and can be achieved by microdialysis. The aim of this pilot study was to demonstrate the proof of principle of long-term subcutaneous microdialysis in humans. For long-term microdialysis, a special setting implementing both concentric and linear catheters has been developed ensuring good clinical practice compliance, tolerability, and convenience for participants and personnel. As a model compound, moderately lipophilic voriconazole was selected as a well-characterized drug in in vitro microdialysis experiments. Multiple in vivo relative recovery (RR) determinations for microdialysis were performed by retrodialysis during the entire study (n = 48 samples). Continuous microdialysis was successfully applied and well tolerated over 87 h in three adults for the first time. RR revealed low intra-individual (coefficient of variation (CV) = 4.4-12.5%) and inter-individual variability (CV = 4.3-12.5%) across all samples and catheters. Lower RR values were consistently determined for linear catheters. One catheter leakage was managed without an impact on the reliability of the RR values. Overall, RR values were calculated to be 73.3% (linear: CV = 18.5%, n = 23) and 84.9% (concentric: CV = 5.6%, n = 23). Long-term microdialysis application over almost 4 days was feasible by reliable multiple RR (proof of principle), well tolerated, and reduced the burden in humans avoiding several catheter insertions, thereby allowing to monitor concentration-time courses continuously. Moreover, a moderately lipophilic drug has been proven suitable for in vivo microdialysis, as previously suggested by in vitro microdialysis.
Collapse
Affiliation(s)
- Franziska Simmel
- Institute of Pharmacy, Department of Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, 06120, Halle, Germany
| | | | | | | | | | | |
Collapse
|
16
|
Bojko B, Cudjoe E, Gómez-Ríos GA, Gorynski K, Jiang R, Reyes-Garcés N, Risticevic S, Silva ÉA, Togunde O, Vuckovic D, Pawliszyn J. SPME – Quo vadis? Anal Chim Acta 2012; 750:132-51. [DOI: 10.1016/j.aca.2012.06.052] [Citation(s) in RCA: 139] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Revised: 06/29/2012] [Accepted: 06/30/2012] [Indexed: 01/01/2023]
|
17
|
Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob Agents Chemother 2012; 56:5852-7. [PMID: 22948869 DOI: 10.1128/aac.01323-12] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The aims of this study were to evaluate free levels of fluconazole (FCZ) in the kidneys of healthy and Candida albicans-infected Wistar rats using microdialysis and to establish the relationship between free renal and total plasma levels under both conditions. Microdialysis recovery rates were determined in vitro by dialysis, and retrodialysis recovery rates were determined in vivo by retrodialysis. The recovery rate was around 50%, independent of the method, drug concentration, or condition (in vitro or in vivo) used. FCZ kidney penetration in healthy and infected rats was investigated after the administration of 10 mg/kg of body weight intravenously (i.v.) or 50 mg/kg orally (n = 6/group) and blood and microdialysate sample harvesting at predetermined time points up to 24 and 18 h, respectively. There were no statistical differences between the area under the free concentration-time curve (AUC(0-∞)) values in plasma and in tissue for either healthy or infected groups for the same dose regimen investigated. The antifungal tissue penetrations were similar for both doses and under all conditions investigated (ranging from 0.77 to 0.84). The unbound fraction of FCZ was concentration independent (86.0% ± 2.0%), allowing the prediction of free renal levels using pharmacokinetic parameters obtained from total plasma fitting. The results showed that free renal and free plasma levels are similar in healthy and systemically C. albicans-infected rats. Therefore, free plasma levels are a good surrogate to estimate free FCZ renal concentrations in systemic candidiasis and can be used to optimize dosing regimens for this drug.
Collapse
|
18
|
de Araujo BV, da Silva CF, Haas SE, Dalla Costa T. Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats. Int J Antimicrob Agents 2008; 33:154-9. [PMID: 19010646 DOI: 10.1016/j.ijantimicag.2008.08.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2008] [Revised: 06/05/2008] [Accepted: 08/08/2008] [Indexed: 11/18/2022]
Abstract
The aims of this study were to evaluate free levels of voriconazole (VCZ) in the kidney of healthy and Candida albicans- or Candida krusei-infected Wistar rats using microdialysis and to establish the relationship between free renal and free plasma levels in both conditions. VCZ (40mg/kg or 60mg/kg) was administered orally (n=6 per group) and blood and microdialysate samples were collected at predetermined time points up to 18h. The mean area under the total concentration-time curve (AUC(0-infinity)) in healthy animals increased from 44.2+/-7.3microg/h/mL to 78.8+/-4.0microg/h/mL for plasma and from 15.1+/-2.4microg/h/mL to 27.9+/-2.6microg/h/mL for tissue after 40mg/kg and 60mg/kg VCZ dosing, respectively, showing non-linear pharmacokinetics described by a one-compartment model with Michaelis-Menten elimination. There were no statistical differences between the AUC(0-infinity) of plasma and tissue for either healthy or infected groups for the same dose. The antifungal tissue penetration was similar for both doses and all conditions investigated (0.34+/-0.06). VCZ protein binding was concentration-independent and was on average 66.0+/-4.0%, allowing the prediction of free renal levels using pharmacokinetic parameters obtained from total plasma fitting. The results showed that VCZ free renal and free plasma levels are similar in healthy rats and in rats with disseminated candidiasis caused by C. albicans or C. krusei. Therefore, plasma free levels can be used to optimise dosing regimens for this drug.
Collapse
Affiliation(s)
- Bibiana Verlindo de Araujo
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, RS, Brazil
| | | | | | | |
Collapse
|